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Background: We hypothesized that telomere length in peripheral 
blood would have significant predictive value for risk of recurrence 
after curative resection in non–small-cell lung cancer (NSCLC).
Methods: This prospective study included 473 patients with histolog-
ically confirmed early stage NSCLC who underwent curative therapy 
at MD Anderson Cancer Center between 1995 and 2008. Relative 
telomere length (RTL) of peripheral leukocytes was measured by real-
time polymerase chain reaction. The risk of recurrence was estimated 
as hazard ratios (HRs) and 95% confidence intervals (CIs) using a 
multivariable Cox proportional hazard regression model.
Results: Median duration of follow-up was 61 months, and 151 
patients (32%) had developed recurrence at time of analysis. Patients 
who developed recurrence had significantly longer mean RTL com-
pared with those without recurrence (1.13 versus 1.07, p = 0.046). A 
subgroup analysis indicates that women had longer RTL compared 
with men (1.12 versus 1.06, p = 0.025), and the patients with adeno-
carcinoma demonstrated longer RTL compared with those with other 
histologic types (1.11 versus 1.05, p = 0.042). To determine whether 
longer RTL in women and adenocarcinoma subgroup would predict 
risk of recurrence, multivariate Cox analysis adjusting for age, sex, 
stage, pack year and treatment regimens was performed. Longer telo-
meres were significantly associated with higher risk of developing 
recurrence in women (hazard ratio [HR], 2.25; 95% confidence inter-
val [CI], 1.02–4.96, p = 0.044) and adenocarcinoma subgroups (HR, 
2.19; 95% CI, 1.05–4.55, p = 0.036). The increased risk of recurrence 
due to long RTL was more apparent in women with adenocarcinoma 
(HR, 2.67; 95% CI, 1.19–6.03, p = 0.018).
Conclusions: This is the first prospective study to suggest that long 
RTL is associated with recurrence in early stage NSCLC after cura-
tive resection. Women and adenocarcinoma seem to be special sub-
groups in which telomere biology may play an important role.
Key Words: Telomere, Telomere length, Telomerase, Early stage 
lung cancer, Non–small-cell lung cancer.
(J Thorac Oncol. 2015;10: 302–308)
Lung cancer is the leading cause of cancer-related death in the United States, with non–small-cell lung cancer 
(NSCLC) accounting for 87% of all cases.1 Surgical resec-
tion in early stage offers the best chance of cure in NSCLC. 
However, even with complete resection, patients are at signifi-
cant risk of recurrence and death from NSCLC.2 Adjuvant cis-
platin-based chemotherapy for completely resected early stage 
NSCLC can offer survival benefit,3–5 but it is not clear which 
subgroup of patients would be at increased risk of developing 
recurrence. Hence, it is important to identify a high-risk group 
of patients who would most likely develop recurrence and 
potentially benefit from adjuvant chemotherapy. Likewise, a 
low-risk subgroup may be spared of toxic chemotherapy regi-
men. A biomarker-driven risk prediction model is necessary in 
molecularly heterogeneous NSCLC.
Telomere pathway is implicated in pathogenesis of vari-
ous types of human cancer. Telomeres are specialized struc-
tures located at chromosome ends consisting of nucleotide 
repeats (TTAGGG)n and ordered protein complex that help 
maintain genomic structural integrity by protecting chromo-
some ends from degradation.6 Progressive shortening of telo-
meres results in critically short telomeres leading to cellular 
crisis.7 However, in cancer cells, up-regulation of telomerase is 
found in approximately 90% of human cancers leading to con-
tinued cellular proliferation.8,9 Several studies have shown an 
association between shorter telomeres in peripheral leukocytes 
and risk of various types of cancer including lung cancer.10,11
There are a number of telomere-associated proteins that 
have essential roles in maintaining telomere length. For exam-
ple, TRF1 and TRF2 are thought to be suppressors of telomere 
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elongation.12,13 POT1 binds the 3′ telomeric overhang and may 
regulate telomerase access.14,15 TPP1 is identified as a regulator 
of POT1.16 Human RAP1 is recruited to the telomere by TRF2 
without directly binding to DNA17 and targeting human RAP1 
with small interference RNA leads to longer telomeres.18 Such 
complexity suggests a highly regulated mechanism of telomere 
pathway that may affect clinical outcome.
There exists a significant interindividual variation in 
telomere length.19,20 Furthermore, genome-wide association 
studies identified single nucleotide polymorphisms in genes 
encoding telomere-associated proteins that are implicated in 
maintaining leukocyte telomere length,21,22 and risk of pancre-
atic,23 skin,24 and lung cancer.25 We hypothesize that telomere 
length in peripheral leukocytes would have significant predic-
tive value for recurrence following curative surgical resection 
in NSCLC, thereby guiding decision for adjuvant chemother-
apy. To the best of our knowledge, this is the first investiga-
tion of the association between telomere length and clinical 
outcome in early stage NSCLC.
MATERIALS AND METHODS
Study Population
This prospective study included 467 patients with his-
tologically confirmed NSCLC, who were enrolled from 1995 
to 2008 in an ongoing epidemiologic lung cancer study at 
MD Anderson Cancer Center. Written informed consent was 
signed by all study participants, and the study was reviewed 
and approved by the Institutional Review Board of MD 
Anderson Cancer Center.
All the study participants had early stage disease (stage 
I and II) and underwent surgery or surgery plus chemotherapy 
(mostly platinum based) or radiotherapy. Each patient was 
interviewed by trained M. D. Anderson staff interviewers to 
collect comprehensive epidemiologic data using structured 
questionnaire. Follow-up data were abstracted from medical 
records for each patient. After the in-person interview, 40 ml 
blood sample was prospectively collected from each partici-
pant and sent to the laboratory for molecular analysis.
Telomere Length Assessment
High-quality genomic DNA was extracted from periph-
eral blood using the QIAamp Maxi DNA kit (Qiagen, Valencia, 
CA) according to the manufacturer’s protocol. The details of 
telomere length assessment have been described previously.26 
The relative overall telomere length was assessed using a mod-
ified version of the real-time quantitative polymerase chain 
reaction (PCR) and was determined by the normalized ratio 
between the telomere repeat copy number and the single gene 
(human globulin) copy number to standardize between differ-
ent runs. The PCR mixture (15 μl) for the telomere amplifi-
cation consisted of 5 ng of genomic DNA, 1× SYBR Green 
Mastermix (Applied Biosystems, Grand Island, NY), 200 
nmol/liter Tel-1, and 200 nmol/liter Tel-2. The PCR mixture 
for human globulin amplification consisted of 5 ng of genomic 
DNA, 1× SYBR Green Mastermix, 200 nmol/liter Hgb-1, 
and 200 nmol/liter Hgb-2. The thermal cycling conditions 
were 95°C for 10 minutes followed by 40 cycles of 95°C for 
15 seconds and 56°C (for telomere amplification) or 58°C 
(for Hgb amplification) for 1 minute. The PCRs for telomere 
and Hgb were done on separate 384-well plate, with the same 
samples in the same well positions. Negative controls, positive 
controls, a calibrator DNA, and a standard curve were included 
in each run. A six-point standard curve was created by diluting 
the reference DNA sample (the same DNA sample for all runs) 
using a twofold increment per dilution (from 20 to 0.625 ng) in 
each reaction.
Statistical Analysis
The primary end point was recurrence (time from diag-
nosis to recurrence or last follow-up). Recurrence was defined 
as evidence of local recurrence or new sites of involvement in 
lymph nodes or distant organ after curative resection. Patients 
who were lost to follow-up or who were alive at the end of the 
study without evidence of recurrence were censored. The asso-
ciation between telomere length and age was assessed by linear 
regression. Student’s t test was used to assess the association 
of telomere length with recurrence. The multivariate Cox pro-
portional hazard model while adjusting for age, sex, ethnicity, 
stage, pack year, and treatment regimens was used to assess the 
effect of telomere length on recurrence. Patients with previously 
diagnosed stage I and II disease who came to MD Anderson for 
treatment after developing recurrence were excluded from the 
Cox proportional hazard analysis of recurrence. All the statisti-
cal analyses above were performed using STATA software (ver-
sion 10.1; Stata Corporation, College Station, TX).
RESULTS
Patient Characteristics
The characteristics of the subjects are shown in Table 1. 
A total of 473 patients who were enrolled between 1995 and 
2008 in an ongoing prospective cohort study and who under-
went curative therapy for early stage NSCLC at MD Anderson 
Cancer Center were included. Adenocarcinoma was the most 
common histology involving 61.5% of patients. A majority 
of patients (73.3%) underwent surgical resection only and the 
remaining 26.7% of patients received either neoadjuvant or 
adjuvant chemotherapy. Median follow-up time was 61 months.
Association of Telomere Length 
with Recurrence and Other 
Clinicopathologic Parameters
Relative telomere length (RTL) results from a total of 
473 peripheral blood samples that were collected at time of 
in-person interview were used for the analysis. Age and RTL 
showed inverse association (θ = −0.00807774; p = 1.50X10-8). 
At the time of analysis, 151 patients (32%) developed recur-
rence. Our results show that recurrence group demonstrated 
significantly longer mean RTL compared with nonrecurrence 
group (1.13 versus 1.07, p = 0.0465) (Table 2 and Fig. 1). In 
addition, women had longer RTL compared with men, and 
the patients with adenocarcinoma demonstrated longer RTL 
compared with those with other histologic types (Table 2 
and Fig. 1). There was no significant association of RTL 
with smoking status, ethnicity, stage of disease, and type of 
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treatment (surgery alone versus surgery plus chemotherapy) 
(Table 2). After adjusting for age, the recurrence remained 
in borderline association (p = 0.076) with telomere length 
whereas the correlation with sex (p = 0.11) and histology 
(p = 0.11) no longer became significant.
Effect of Telomere Length on Risk of Recurrence
The effect of RTL on risk of recurrence after curative 
therapy in NSCLC was assessed. Multivariable Cox propor-
tional analysis on 427 patients after adjusting for age, sex, eth-
nicity, stage, pack year, and treatment regimens showed that 
longer telomeres were associated with higher risk of develop-
ing recurrence at borderline statistical significance (hazard ratio 
[HR], 1.75; 95% confidence interval [CI], 0.96–3.22, p = 0.070) 
(Table 3). Given the results from the previous section demon-
strating association of long telomeres with women sex and 
adenocarcinoma histology, a subgroup analysis was conducted. 
The increased risk of recurrence due to long RTL was more pro-
nounced and statistically significant in women (HR, 2.25; 95% 
CI, 1.02–4.96, p = 0.044) and adenocarcinoma (HR, 2.19; 95% 
CI, 1.05–4.55, p = 0.036) subgroups (Table 3). Moreover, in 
women with adenocarcinoma, a higher risk of recurrence due to 
long RTL was estimated and was highly significant (HR, 2.67; 
95% CI, 1.19–6.03, p = 0.018) (Table 3). Kaplan–Meier curves 
and log-rank tests comparing long versus short RTL dichoto-
mized by the median telomere length are shown in Figure 2. 
Figure 2D reinforces the finding that the difference in the risk 
of recurrence between long versus short RTL is particularly 
significant in women patients with adenocarcinoma histology 
(p = 0.033). Long RTL was borderline associated with recur-
rence in an ever-smoker subgroup (p = 0.054).
DISCUSSION
We report novel findings that early stage NSCLC patients 
who develop recurrence after curative therapy had longer blood 
telomeres compared with the patients without recurrence. 
Although several past studies associated short telomeres with 
increased risk of lung cancer,10,27,28 we need to emphasize that our 
study subjects had newly diagnosed early stage disease, and the 
blood samples were collected before undergoing chemotherapy 
TABLE 1.  Patient Characteristics
Median follow-up time (months) 61.02
Age, median (range) 66.0 (29–86)
Total number of patients 473
Variables N %
Sex
  Men 232 49
  Women 241 51
Ethnicity
  White 418 88.4
  Black 35 7.4
  Others 20 4.2
Smoking status
  Never 65 13.7
  Former 241 51
  Current 167 35.3
Clinical stage
  Stage IA 212 44.8
  Stage IB 170 35.9
  Stage IIA 24 5.1
  Stage IIB 67 14.2
Pathologic stage
  Stage 0 2 0.4
  Stage IA 185 40.4
  Stage IB 164 35.8
  Stage IIA 27 5.9
  Stage IIB 80 17.5
Histology
  Adenocarcinoma 291 61.5
  Squamous cell carcinoma 121 25.6
  Other 61 12.8
Treatment
  Surgery only 332 70.2
  Adjuvant chemotherapy 89 18.8
  Neoadjuvant chemotherapy 32 6.8
  Other 20 4.2
Type of surgery
  Wedge resection only 52 11
  Lobectomy only 310 65.5
  Pneumonectomy only 23 4.9
  Other 88 18.6
TABLE 2.  Relationship between Leukocyte Telomere Length 
and Various Clinicopathologic Parameters
Variables n Mean (SD) p Value
Age 473 1.09 (0.32) 1.50x10-8
Sex
  Men 232 1.06 (0.31) 0.025
  Women 241 1.12 (0.32)
Smoking status
  Never 65 1.14 (0.36) 0.137
  Ever 408 1.08 (0.31)
Recurrence
  No 322 1.07 (0.31) 0.0465
  Yes 151 1.13 (0.33)
Histology
  Adenocarcinoma 291 1.11 (0.32) 0.042
  Others 182 1.05 (0.30)
Ethnicity
  White 418 1.09 (0.31) 0.611
  Others 55 1.11 (0.34)
Stage
  1 382 1.09 (0.32) 0.933
  2 91 1.09 (0.30)
Treatment
  Surgery only 332 1.10 (0.32) 0.28
  Surgery + chemo 121 1.07 (0.29)
Bold denotes P values < 0.05.
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excluding the possibility of chemotherapy-induced change in telo-
mere length. In addition, Pooley et al.29 reported that mean telo-
mere length was shorter in retrospectively collected cases than in 
controls, but the association was markedly weaker in the prospec-
tive studies, suggesting that telomere shortening may occur after 
diagnosis. A recent prospective cohort study involving Chinese 
women demonstrated that longer RTL in blood may be associated 
with increased risk of lung cancer.30 In addition, two other studies 
by Svenson et al.31,32 showed that longer RTL was associated with 
worse prognosis in breast cancer and clear cell renal cell carci-
noma (ccRCC) consistent with our finding. Interestingly, the study 
involving ccRCC showed that long blood RTL was associated 
with poor survival only in patients with nonmetastatic ccRCC, 
possibly suggesting dynamic changes in telomere biology during 
tumor progression. Though telomere biology of NSCLC may be 
different from that of other tumor types, these support our find-
ings of long RTL in peripheral blood as a potential biomarker for 
increased risk of recurrence in early stage NSCLC.
The potential mechanisms for long telomere as a poor 
prognostic marker are not well established in the literature but are 
thought to be complex, reflecting a combined effect of epigenetic 
regulation, cytokines, and hormones.31,32 We can speculate that 
longer telomeres are secondary to increased telomerase activity 
that stabilizes telomere length and are therefore less susceptible 
to apoptosis, potentially contributing to increased number of 
viable tumor cells. In addition, longer telomeres generally rep-
resent actively reproducing cells that are at an increased risk of 
acquiring tumor-causing mutations, whereas short telomeres may 
induce cellular senescence.33,34 High levels of telomerase activity 
are seen in 80% to 85% of all NSCLCs and are associated with 
advanced stages of NSCLC.35,36 In addition, telomerase activity 
can be enhanced by various circulating cytokines37–39 that were 
detected at higher serum levels in untreated lung cancer.40,41 Our 
finding is also supported by a recent study by Robles-Espinoza 
et al.42 that reported a mutation in the protection of telomeres 
(POT1) gene that predisposes to development of familial mela-
noma that is strongly associated with longer telomeres. The caveat 
to above hypotheses is that telomere pathway in leukocytes may 
not reflect what is occurring in tumor cells. We are limited by the 














n HR 95% Lower 95% Upper p Value
All patients 427 1.75 0.96 3.22 0.070
Age ≤65 204 1.88 0.84 4.22 0.13
Age >65 223 1.52 0.58 3.98 0.40
Men 209 1.15 0.40 3.26 0.79
Women 218 2.25 1.02 4.96 0.044
White 381 1.65 0.87 3.16 0.13
Others 46 8.91 0.63 125.68 0.11
Never smoker 56 0.12 0.01 1.90 0.13
Ever smoker 371 1.88 0.99 3.57 0.054
Adenocarcinoma 262 2.19 1.05 4.55 0.036
Other histology type 165 1.10 0.34 3.56 0.87
Stage I 341 1.52 0.74 3.12 0.25
Stage II 86 2.53 0.76 8.48 0.13
Surgery only 287 1.90 0.86 4.23 0.11
Surgery + chemo 120 1.10 0.35 3.51 0.87
Women + adenocarcinoma 163 2.67 1.19 6.03 0.018
Bold denotes P values <0.05.
aAdjusted for age, sex, ethnicity, stage, pack year, and treatment regimens.
HR, hazard ratio.
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shared with cancer cells. This assumption may be supported by a 
recently published study by Daniali et al.43 which demonstrated 
that telomere lengths strongly correlated between tissues.
Our data also suggest that impact of longer telomere 
length on increased risk of recurrence was more pronounced 
in women and adenocarcinoma subgroups. This finding is con-
sistent with our recently published study demonstrating that 
patients with adenocarcinoma had longer telomere length than 
that of the healthy controls, whereas patients with squamous 
cell carcinoma had shorter telomere length.44 This is further 
supported by an independent study that demonstrated a pro-
nounced association between telomere length and lung can-
cer risk in women adenocarcinoma cases.45 Longer telomeres 
in women were reported in several other studies including a 
recent meta-analysis.46–48 Estrogen may explain sex difference 
with respect to telomere length. In support of this, postmeno-
pausal women with a history of long-term hormone replace-
ment therapy had longer blood telomeres than postmenopausal 
women without hormone replacement therapy.49 Estrogen can 
also influence telomere length by activation of the human 
telomerase reverse transcriptase (hTERT) gene promoter and 
by posttranscriptional regulation of hTERT.50,51 Furthermore, 
a recent prospective cohort study among women in China by 
Lan et al.30 reported that women with longer telomere length 
in peripheral white blood cells may have an increased risk of 
developing lung cancer consistent with our finding. It is also 
intriguing that longer telomere length predicted increased risk 
of recurrence only in patients with adenocarcinoma. Telomere 
pathway may be one of the necessary steps for pathogenesis 
in adenocarcinoma that is molecularly distinct from other his-
tology types. Kuhn et al.52 reported that RTL significantly dif-
fers by histologic type in ovarian cancer. Specifically, longer 
telomeres in clear cell ovarian carcinoma are associated with 
increased mortality suggesting that aberrations in telomere 
length may impact progression of tumor. A different study by 
Hirashima et al.53 demonstrated that forced elongation of the 
telomeres in cancer cells promoted their differentiation in vivo. 
The resulting cells had longer telomeres and were capable of 
forming tumors in nude mice that surprisingly exhibited many 
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speculate that long telomere length could potentially contribute 
to tumor recurrence by regulation of cancer cell differentiation, 
especially into adenocarcinoma subtype. It is also worth noting 
that smoking-related NSCLC despite borderline significance in 
Table 3 may be an important subgroup in which telomere length 
may have a predictive value for recurrence. Further mechanical 
studies are necessary to understand our findings better.
It may be worth noting that mutations in the epidermal 
growth factor receptor (EGFR) that predict increased sensitiv-
ity to the EGFR tyrosine kinase inhibitors in NSCLC occur 
more frequently in women and adenocarcinoma histology.54–58 
Several studies suggest potential associations between telomere 
biology and EGFR signaling pathway. Heeg et al.59 reported 
that EGFR overexpression induces activation of telomerase by 
means of PI3K/AKT-mediated phosphorylation. Another study 
involving clinical specimens of human salivary gland carci-
nomas reported a significant correlation between telomerase 
activity and mRNA expression of EGFR.60 Furthermore, epi-
dermal growth factor up-regulated telomerase activity in EGFR-
positive cells after the activation of TERT mRNA expression.61 
This suggests that epidermal growth factor activates telomer-
ase through the direct activation of TERT transcription. Even 
though there is no study, to our best knowledge, demonstrating 
relationship between telomere length and EGFR mutation sta-
tus, it may warrant further investigation. Because most of our 
study subjects were enrolled in the study before our knowledge 
about sensitizing EGFR mutations, EGFR mutation status in 
tumors of our patient population is not available.
The major strengths of our study include use of a large 
number of well-characterized early stage NSCLC patients 
with detailed clinical information, reliable assay for telo-
mere length measurement, and a prospective cohort design. 
Furthermore, our study adjusted for multiple potential con-
founding variables such as age, sex, ethnicity, stage, pack year, 
and treatment regimens. A major limitation of our study is that 
in contrast to studies involving metastatic NSCLC patients, 
our early stage NSCLC population had relative low number 
of events, which resulted in relatively small sample sizes in 
some subgroups. Our findings will need to be validated ideally 
targeting specific subgroups (women, adenocarcinomas, etc.) 
and in an independent patient population before clinical use.
In conclusion, this is the first large-scale study evaluat-
ing the impact of telomere length on predicting risk of recur-
rence after curative resection in early stage NSCLC patients. 
Our data support long telomere as a predictor for increased 
risk of recurrence, especially in women patients with adeno-
carcinoma. Our findings will need to be validated in an inde-
pendent patient population with a special focus in women and 
adenocarcinoma subgroups before being utilized in clinical 
practice. Nevertheless, leukocyte telomere length appears to 
be a promising biomarker that can modulate clinical outcome 
in early stage NSCLC patients.
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